<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04845516</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL21_0084</org_study_id>
    <nct_id>NCT04845516</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerance of Therapeutic Apheresis in Paediatric Neurology: a French Multicenter Study</brief_title>
  <official_title>Efficacy and Tolerance of Therapeutic Apheresis in Paediatric Neurology: a Retrospective French Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      After developing in pediatric hematology and nephrology, therapeutic apheresis is&#xD;
      increasingly used in pediatric neurology despite a sparse level of evidence.&#xD;
&#xD;
      There are a few retrospective series with a small number of patients, concerning mainly&#xD;
      autoimmune diseases (encephalitis, myasthenia gravis, polyradiculoneuritis).&#xD;
&#xD;
      The objective of this work is to study therapeutic apheresis (including plasma exchange and&#xD;
      immunoadsorption) among french neuropediatric tertiary centers and to prove that this&#xD;
      treatment modality is effective and well tolerated in pediatric neurology diseases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter medical data collection :&#xD;
&#xD;
        -  Montpellier&#xD;
&#xD;
        -  Toulouse&#xD;
&#xD;
        -  Bordeaux&#xD;
&#xD;
        -  Marseille&#xD;
&#xD;
        -  Nancy&#xD;
&#xD;
        -  Paris Kremlin Bicêtre&#xD;
&#xD;
        -  Paris Robert Debré&#xD;
&#xD;
        -  Paris Necker&#xD;
&#xD;
        -  Paris Trousseau&#xD;
&#xD;
        -  Lyon&#xD;
&#xD;
        -  Besançon&#xD;
&#xD;
        -  Rennes&#xD;
&#xD;
        -  Reims&#xD;
&#xD;
        -  Strasbourg&#xD;
&#xD;
        -  La Réunion&#xD;
&#xD;
        -  Nantes&#xD;
&#xD;
        -  Tours&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>global neurological efficacy of therapeutic apheresis as assessed</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>lobal neurological efficacy of therapeutic apheresis as assessed by modified rankin score Modifed Rankin score, ranging from 0 (no symptoms) to 6 (death)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of therapeutic apheresis adverse events as assessed</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>tIncidence of therapeutic apheresis adverse events as assessed by low blood tension rate, transfusion rate, infection rate, hypocalcaemia rate, thrombosis rate, allergy rate, anemia rate, hemostasis disorders rate).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adjuvant treatments</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>Incidence of adjuvant treatments (corticosteroid therapy, immunoglobulins, immunosuppressants),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hospitalization in intensive care</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>Incidence of hospitalization in intensive care, intubation rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the therapeutic apharesis modalities</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>number of procedures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the therapeutic apharesis modalities</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>exchanged volume (in plasma volume percentage) for each procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the therapeutic apharesis modalities</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>type of separation et number of participants with ttt-related advesre events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the therapeutic apharesis modalities</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>type of replacement solution (isotonic saline, albumin, fresh frozen plasma)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participitants with treatment-related adverse events</measure>
    <time_frame>during procedures</time_frame>
    <description>rate of arterial hypotension (&lt; age standards and and requiring isotonic saline bolus, for each patient and for procedure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participitants with treatment-related adverse events</measure>
    <time_frame>during procedures</time_frame>
    <description>rate of hypocalcemia (ionized calcium &lt;1,1 mmol/L, for each patient and for each procedure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participitants with treatment-related adverse events</measure>
    <time_frame>during procedures</time_frame>
    <description>rate of hypoalbuminemiafor for each patient and for each procedure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participitants with treatment-related adverse events</measure>
    <time_frame>during procedures</time_frame>
    <description>rate of thrombosis (confirmed by a CT scan or ultrasound, for each patient)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participitants with treatment-related adverse events</measure>
    <time_frame>during procedures</time_frame>
    <description>rate of infections related catheter (for each patient)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participitants with treatment-related adverse events</measure>
    <time_frame>during procedures</time_frame>
    <description>rate of allergics reactions (for each patient and for each procedure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participitants with treatment-related adverse events</measure>
    <time_frame>during procedures</time_frame>
    <description>rate of anemia (Hb &lt; 7,0 g/dL, for each patient)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participitants with treatment-related adverse events</measure>
    <time_frame>during procedures</time_frame>
    <description>rate of transfusion (for each patient)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participitants with treatment-related adverse events</measure>
    <time_frame>during procedures</time_frame>
    <description>rate of haemostasis disorder (platelets &lt; 100 &lt;G/L ; TQ &lt; 40 % ; fibrinogen &lt; 1 G/L ; (for each patient and for each procedure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participitants with treatment-related adverse events</measure>
    <time_frame>during procedures</time_frame>
    <description>rate of death</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Apheresis Related Complication</condition>
  <arm_group>
    <arm_group_label>plasma exchange</arm_group_label>
    <description>All patients underwent plasma exchanges between 2014 and 2019 for a neuropediatric pathology</description>
  </arm_group>
  <arm_group>
    <arm_group_label>immunoadsorption</arm_group_label>
    <description>All patients who underwent immunoadsorptions between 2014 and 2019 for a neuropediatric pathology</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Efficacy of apheresis</intervention_name>
    <description>Efficacy of apheresis</description>
    <arm_group_label>immunoadsorption</arm_group_label>
    <arm_group_label>plasma exchange</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Children under 18, Supported in a participating CHU between 2014 and 2019 and Having&#xD;
        benefited from therapeutic apheresis (plasma exchanges and immunoadsorption) in a&#xD;
        neuropediatric indication&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Children under 18.&#xD;
&#xD;
          -  Supported in a participating CHU between 2014 and 2019.&#xD;
&#xD;
          -  Having benefited from therapeutic apheresis (plasma exchanges and immunoadsorption) in&#xD;
             a neuropediatric indication&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        - Family or patient refusal to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maxime colmard, résident</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals of Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre Meyer, MD</last_name>
    <phone>672646907</phone>
    <phone_ext>33</phone_ext>
    <email>p-meyer@chu-montpellier.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maxime colmard, résident</last_name>
    <phone>672646907</phone>
    <phone_ext>33</phone_ext>
    <email>maxime.colmard@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Uh Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maxime Colmard</last_name>
      <phone>672646907</phone>
      <phone_ext>33</phone_ext>
      <email>maxime.colmard@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 16, 2021</study_first_submitted>
  <study_first_submitted_qc>April 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2021</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Children</keyword>
  <keyword>therapeutic exchange</keyword>
  <keyword>neuropediatric</keyword>
  <keyword>immunoadsorption</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

